Long-term safety of ONO-4538 in people with various cancers
Checks long-term safety of ONO-4538 in people with cancer continuing prior treatment.
Key facts
- Who runs it
- Ono Pharmaceutical Co., Ltd.
- Where
- Daegu, Gyeonggi-do, Hwasun, Incheon, Seoul, and Suwon, South KoreaSee the 13 sitesAlso in 2 other countries, 31 sites
- Trial code
- NCT04566380
- JRCT2080225345
- Registry title
- ONO-4538 Phase II Rollover Study (ONO-4538-98)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 70 people, planned
- Started
- 10 Sept 2020
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- ONO-4538
- oxaliplatin
- S-1
- capecitabine
- bevacizumab
- temozolomide
- Ipilimumab
- ONO-7703
- Record updated
- 14 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with cancer who are already being treated with ONO-4538, alone or with other therapies, in another clinical trial and are continuing that treatment.
- Age
- 16 years or older
- Sex
- All sexes can join
- Disease stage
- Any tumor type (pan-tumor); the person must be getting ONO-4538 in a clinical trial.
- Earlier treatment
- Must currently be treated with ONO-4538, alone or with other therapies, in a clinical trial.
Main reasons for not taking part
- Cannot give consent, for example because of dementia
- The investigator judges the person inappropriate for this study
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Participant who is being treated with ONO-4538 as monotherapy or in Combination with Other Therapies in clinical trials
- Participant who is eligible for ONO-4538 monotherapy or in combination with other therapies as per the clinical trials, and/or investigator-assessed clinical benefit
Who cannot take part
- Participant judged to be incapable of providing consent for reasons such as concurrent dementia
- Participant judged by the investigator to be inappropriate as participants of this study
Where in South Korea
Also in 2 other countries, 31 sites
- DaeguHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
- Daegu, South KoreaHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
- DaeguHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
- Gyeonggi-doHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
- HwasunHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
- IncheonHospital not named in the registryContact: North America Clinical Trial Support DeskNo longer taking part
- SeoulHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
- SeoulHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
- SeoulHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
- SeoulHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
- SeoulHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
- SeoulHospital not named in the registryContact: North America Clinical Trial Support DeskNo longer taking part
- SuwonHospital not named in the registryContact: North America Clinical Trial Support DeskTaking people
About the trial
What the trial wants to find out
This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.
The 2 groups in the trial
- ONO-4538 Monotherapy cohortTreatment being tested
480 mg of ONO-4538 IV Q4W or 240 mg of ONO-4538 IV Q2W per the investigator's choice
Treatment: ONO-4538
- Combination therapy cohortTreatment being tested
ONO-4538 at 360 mg IV Q3W or 480 mg IV Q4W, and Combination therapies (S-1 + Oxaliplatin \[SOX\] therapy , Capecitabine + Oxaliplatin \[CapeOX\] therapy , Bevacizumab, Temozolomide, Ipilimumab + SOX therapy, Ipilimumab + CapeOX therapy or ONO-7703) selected by the principal investigator or subinvestigator in the Parent Study will be continued in this study.
Treatment: ONO-4538, oxaliplatin, S-1, capecitabine, bevacizumab, temozolomide, Ipilimumab, and ONO-7703
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Open-label, Phase II Pan-Tumor Study in Patients Who Have Participated in Trials to Investigate Efficacy and Safety of ONO-4538 as Monotherapy or in Combination With Other Therapies and Are Continuing ONO-4538 Treatment (ONO-4538-98)
- Plain-language title
- Long-term safety of ONO-4538 in people with various cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 14 October 2026